ABBV

AbbVie (ABBV) U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

4 weeks ago

AbbVie (NYSE: ABBV) FY 2026 Other Release

4 weeks ago

AbbVie (NYSE: ABBV) Q1 2026 Dividend Update

4 weeks ago

S&P 500 gains 0.52% as energy surges 1.84% and tech adds 1.34%, while utilities tumble 1.68% in risk-on rotation.

1 month ago

AbbVie (NYSE: ABBV) Q4 2025 Earnings Conference

2 months ago

AbbVie (NYSE: ABBV) Q2 2025 Earnings Call dated Jul. 31, 2025 Corporate Participants: Liz Shea — Senior Vice President, Investor…

2 months ago

AbbVie (NYSE: ABBV) Q3 2025 Earnings Call dated Oct. 31, 2025 Corporate Participants: Liz Shea — Senior Vice President of…

8 months ago

AbbVie (NYSE: ABBV) reported its second quarter 2025 earnings results today. Worldwide net revenues were $15.4 billion, up 6.6% on…

3 years ago

AbbVie (NYSE: ABBV) reported second quarter 2023 earnings results today. Worldwide net revenues were $13.8 billion, down 4.9% on a…

3 years ago

AbbVie (NYSE: ABBV) Q1 2023 Earnings Call dated Apr. 27, 2023 Corporate Participants: Elizabeth Shea — Senior Vice President of…

3 years ago

AbbVie (NYSE: ABBV) Q4 2022 earnings call dated Feb. 09, 2023 Corporate Participants: Elizabeth Shea — Vice President, Investor Relations Richard A.…